Register entry
- Registered sites
- 0
- Active NDC listings
- 4
- Labeller names
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
44 active NDC listings: 3 drug for further processing, 1 bulk ingredient. By marketing category: DRUG FOR FURTHER PROCESSING 3, BULK INGREDIENT 1.
| Dosage form | NDCs |
|---|---|
| tablet | 2 |
| liquid | 1 |
| powder | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| f. hoffmann-la roche ltd | 3 |
| f. hoffmann-la roche ag | 1 |
Catalogue
Marketed products
4| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | BALOXAVIR MARBOXIL | tablet | 12806-8600DRUG FOR FURTHER PROCESSING |
| - | BALOXAVIR MARBOXIL | tablet | 12806-8770DRUG FOR FURTHER PROCESSING |
| - | Entrectinib | powder | 12806-0090BULK INGREDIENT |
| - | atezolizumab | liquid | 12806-0917DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing baloxavir marboxil
- Genentech, Inc.8 sites · 93 NDC
- Sportpharm LLC0 sites · 261 NDC
Enquiry
Common questions
- Is F. Hoffmann-La Roche Ltd FDA approved?
- F. Hoffmann-La Roche Ltd holds no registered establishment of its own; 4 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does F. Hoffmann-La Roche Ltd make?
- 4 products are listed under F. Hoffmann-La Roche Ltd in the openFDA NDC Directory, most often as tablet; liquid; powder. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.